This clinical trial focuses on studying the effects of Multiple Sclerosis and providing continued access to a treatment called Ocrelizumab. Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms such as problems with vision, arm or leg movement, sensation, or balance. The treatment being studied, Ocrelizumab, is available in two forms: a 920 mg solution for injection and a 300 mg concentrate for solution for infusion. The purpose of the study is to understand the physical impact of Multiple Sclerosis from the patient’s perspective and to ensure that patients who were previously part of a related study can continue receiving Ocrelizumab.

Participants in this study will receive Ocrelizumab either as an injection under the skin or as an infusion into a vein. The study will last for a period of up to five years, during which the physical effects of Multiple Sclerosis on patients will be evaluated. The study will also monitor the number of participants who continue to receive Ocrelizumab and any side effects they may experience. This study is an extension of previous research, allowing patients who do not have access to Ocrelizumab locally to continue their treatment.

The study aims to gather information on how patients perceive the physical impact of Multiple Sclerosis while continuing their treatment with Ocrelizumab. This information will help in understanding the long-term effects of the treatment and its impact on patients’ quality of life. Participants will be monitored for any serious side effects or adverse events that may occur during the study period. The study is designed to provide valuable insights into the management of Multiple Sclerosis and the role of Ocrelizumab in improving patient outcomes.